Evidence map›Paper›PMID 34252296›Full record

ArticleAntimicrobial agents and chemotherapy2021

Genetic Context of

Michael Biggel, Magdalena Nüesch-Inderbinen, Christoph Jans, Marc J A Stevens, Roger Stephan

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. TransferableApplied and environmental microbiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Co-Existence of Oxazolidinone Resistance GenesAntibiotics (Basel, Switzerland) · 2023
    Article
  14. Detection of anAntibiotics (Basel, Switzerland) · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael BiggelInstitute for Food Safety and Hygiene, Vetsuisse Faculty University of Zürich, Zürich, Switzerland.ORCID 0000-0002-1337-2132
Magdalena Nüesch-InderbinenInstitute for Food Safety and Hygiene, Vetsuisse Faculty University of Zürich, Zürich, Switzerland.ORCID 0000-0002-3242-9739
Christoph JansAmt für Verbraucherschutz, Steinhausen, Zug, Switzerland.
Marc J A StevensInstitute for Food Safety and Hygiene, Vetsuisse Faculty University of Zürich, Zürich, Switzerland.
Roger StephanInstitute for Food Safety and Hygiene, Vetsuisse Faculty University of Zürich, Zürich, Switzerland.ORCID 0000-0003-1002-4762
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Linezolid is an important last-resort antibiotic for the treatment of multidrug-resistant enterococci. The aim of this study was to further characterize the genetic context of

Indexed as

Enterococcus faeciumGram-Positive Bacterial InfectionsAnti-Bacterial AgentsDrug Resistance, BacterialEnterococcusEnterococcus faecalisHumansSwitzerlandThiamphenicolWaterAnti-Bacterial AgentsflorfenicolThiamphenicolWaterEnterococcuslinezolid resistanceoptrApoxtAsurface water

Identifiers

PMID34252296
PMCPMC8448137
OpenAlexW3182077093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.